Philippe Roingeard
  • E-mail :[email]
  • Phone : +33 (0) 2 34 37 96 46
  • Location : Tours, France
Last update 2014-04-02 10:44:13.305

Philippe Roingeard PharmD. Ph.D

Course and current status

1. Civil Status: Born on March, 16, 1961 in Tours (France), French Citizenship

2. Degrees and Diplomas:

1984            PharmD.             François Rabelais University, Tours           

1988             PhD.                  François Rabelais University, Tours           

3. Additional training:                                     

May 88 - Dec 90          Research Associate, Department of Cancer Biology,

                                    School of Public Health, Harvard University, Boston, MA.

4. University positions:

Jan 91 - Aug 01         Assistant-Professor & Hospital Biologist

Since Sept 01            Professor & Hospital Biologist           

                                  Medical School & Bretonneau Hospital,

                                  François Rabelais University, Tours                       

5. Main administrative responsibilities:

- Head of the INSERM U966 "Morphogenesis and Antigenicity of HIV and hepatitis viruses" (http://mavivh.univ-tours.fr)

-Head of the join PhD. program in Health & Biology of the Tours and Orléans Universities (Centre Val de Loire Universities) (http://recherche-valorisation.univ-tours.fr/ssbcv)

- Head of the Electron Microscopy Facility, François Rabelais University, Tours (http://microscopies.med.univ-tours.fr)

- Head of the Cell Biology Unit, Medical Biology Department, Tours University Hospital (CHU)

- Elected member of the National University Committee (CNU) - Medicine, Cell Biology.

 

Scientific summary

Selection and description of the main publications during the last ten years :

Blanchard E et al, J Virol  2002; 76, 4073-4079.

Blanchard E  et al, J Virol  2003; 77, 10131-10139.

Roingeard P et al, Biol Cell 2004; 96, 103-108.                       

Hourioux C et al, Cell Microbiol 2007 ; 9, 1014-1027.

These studies consisted in the development of a original model to study the hepatitis C virus (HCV) morphogenesis and understand the virus/host cell interactions during the late stages of the viral infectious cycle. In the absence of virus propagation system at this time, this model has played an important role in understanding the biology of HCV. These studies, in the context of a highly competitive field, have enhanced the visibility of the team at national and international level and generated a large number of collaborations on  virus/cell interactions for various models.

 

Hourioux C et al, Gut 2007 ; 56, 1302-1308.

Roingeard P et al, J Viral Hepat 2008 ;15, 157-164.

Depla M et al, Cell Mol Life Sci 2010 ; 67, :3151-61.

Roingeard & Depla, Biol Cell 2011 ; 103, 223-231.

Depla M et al, PLoS One 2012 ; 7, e33749.

In continuation of these previous studies, our cell system was used to model in vitro the steatosis induced by HCV. We showed that the capsid protein of the virus was responsible for the accumulation of lipid droplets and the variability of this protein could modulate the importance of this mechanism. Our model allowed us to modelize in vitro the impact of the viral genotype on fatty liver. This work gave the basis for a clinical research project "Virosteatosis" which was funded by the call "Translational Research" INSERM-DHOS.

 

Patient R et al, J Virol 2007 ; 81, 3842-3851.

Patient R et al, N Biotechnol  2009 ; 25, 226-234.

Roingeard et al, Patent N° PCT/FR2009/051142 (15 Juin 2009).

Beaumont E et al, Hepatology 2013 ; 57, 1303-1313.

These publications form a continuum, ranging from fundamental work (on the morphogenesis of subviral particles of the hepatitis B virus -HBV- envelope) to very applied research (concerning the development of a bivalent vaccine that could protect against both HBV and HCV). In the absence of a prophylactic vaccine against hepatitis C, the concept of bivalent "HBV-HCV" vaccine has been the subject of an international patent. I was awarded a " Mérieux Research Grant " to assess the potential of the bivalent vaccine in partnership with Mérieux Institute.

Image d’exemple